Cargando…

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience

PURPOSE: Monitoring mutation status in circulating free DNA (cfDNA) during target therapy could hold significant clinical importance in non-small cell lung cancer (NSCLC). Our aim is to establish if EGFR mutational status change on cfDNA has predictive value that can impact clinical management of NS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ianza, Anna, Di Chicco, A., Biagi, C., Giudici, F., Dicorato, A., Guglielmi, A., Variola, F., Tomasi, S., Roviello, G., Generali, D., Zanconati, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article – Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236477/ https://www.ncbi.nlm.nih.gov/pubmed/34003366 http://dx.doi.org/10.1007/s00432-021-03658-8

Ejemplares similares

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer
por: Theard, Patricia L, et al.
Publicado: (2020)

Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma
por: D’Angelo, Alberto, et al.
Publicado: (2019)

Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
por: Zhu, Yan-juan, et al.
Publicado: (2017)

Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair
por: Ganzinelli, Monica, et al.
Publicado: (2023)

Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer
por: Sobhani, Navid, et al.
Publicado: (2020)

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
por: Douillard, Jean-Yves, et al.
Publicado: (2014)

Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
por: Yi, Lilan, et al.
Publicado: (2019)

Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
por: Zeng, Hao, et al.
Publicado: (2019)

Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC
por: Wang, Jinguang, et al.
Publicado: (2018)

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients
por: Villalva, Claire, et al.
Publicado: (2013)

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations
por: Wang, Huijuan, et al.
Publicado: (2019)

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
por: Garrido, Pilar, et al.
Publicado: (2021)

A Case–Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection
por: Bortul, Marina, et al.
Publicado: (2023)

Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
por: Chua, Khi Pin, et al.
Publicado: (2021)

Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs
por: Leonetti, Alessandro, et al.
Publicado: (2021)

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis
por: Luo, Jie, et al.
Publicado: (2014)

Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients
por: He, Changlong, et al.
Publicado: (2021)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
por: Kuiper, J L, et al.
Publicado: (2016)

Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer
por: Ianza, Anna, et al.
Publicado: (2021)

A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR‐TKI resistance
por: Wang, Wenxian, et al.
Publicado: (2016)

Probing of breast cancer using a combination of plasma and urinary circulating cell-free DNA
por: Zuo, Zhigang, et al.
Publicado: (2020)

Sputum cell‐free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR‐TKIs
por: Wang, Zheng, et al.
Publicado: (2021)

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma
por: Krug, A K, et al.
Publicado: (2018)

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
por: Groenendijk, Floris H, et al.
Publicado: (2015)

Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
por: Bjaanæs, Maria Moksnes, et al.
Publicado: (2014)

Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment
por: Su, Po‐Lan, et al.
Publicado: (2019)

The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta‐analysis
por: Xie, Wenli, et al.
Publicado: (2019)

Cellular Therapy in NSCLC: Between Myth and Reality
por: Imbimbo, Martina, et al.
Publicado: (2023)

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations
por: Yang, Yudie, et al.
Publicado: (2022)

Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH
por: Swiatnicki, Matthew R., et al.
Publicado: (2022)

Heterogeneous distribution of EGFR mutation in NSCLC: Case report
por: Boukansa, Sara, et al.
Publicado: (2023)

The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC
por: Yang, Yang, et al.
Publicado: (2017)

Detection of mutations in circulating cell‐free DNA in relation to disease stage in colorectal cancer
por: Liebs, Sandra, et al.
Publicado: (2019)

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment
por: de Langen, Adrianus J., et al.
Publicado: (2018)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

DNA repair deficiency as circulating biomarker in prostate cancer
por: Catalano, Martina, et al.
Publicado: (2023)

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
por: Del Re, Marzia, et al.
Publicado: (2016)

Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer
por: Roviello, Giandomenico, et al.
Publicado: (2017)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7iln4h560ecsl5d44uj0ro9cmk